Search

Your search keyword '"Baffa, Alessandra"' showing total 11 results
Start Over Author "Baffa, Alessandra"
11 results on '"Baffa, Alessandra"'

2. Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial

Author

Manzini, Paola Maria, Ciccone, Giovannino, De Rosa, Francesco Giuseppe, Cavallo, Rossana, Ghisetti, Valeria, D’Antico, Sergio, Galassi, Claudia, Saccona, Fabio, Castiglione, Anna, Birocco, Nadia, Francisci, Tiziana, Hu, Huijing, Pecoraro, Clara, Danielle, Franca, Labanca, Luciana, Bordiga, Anna Maria, Lorenzi, Marco, Camisasca, Giovanni, Giachino, Osvaldo, Pagliarino, Mauro, Ottone, Piero, Scuvera, Ilvana Tiziana Donatella, Guaschino, Roberto, Freilone, Roberto, Berti, Pierluigi, Pittaluga, Fabrizia, Avolio, Maria, Costa, Cristina, Raso, Samuele, Nucci, Aurora, Milan, Massimo, Baffa, Alessandra, Russo, Alessandra, Tornello, Antonella, Maddalena, Laura, Delios, Grazia, Marletto, Fabio Paolo, De Micheli, Anna Grazia, Mattei, Alessio, Baldassano, Stefano, Canta, Francesca, Russo, Maria Luisa, Bergamo, Daniele, Vitale, Francesco, Liccardi, Marco Maria, Chinaglia, Alessandra, Calcagno, Andrea, Converso, Marcella, Aldieri, Chiara, Libanore, Valentina, Blangetti, Ilaria, Benedetti, Valentina, Mitola, Barbara, and Scozzari, Gitana

Published
2022
Full Text
View/download PDF

5. Focal segmental glomerular sclerosis can be effectively treated using an intensive B-cell depletion therapy.

Author

Roccatello, Dario, Baffa, Alessandra, Naretto, Carla, Barreca, Antonella, Cravero, Raffaella, Roscini, Elisabetta, Sciascia, Savino, and Fenoglio, Roberta

Subjects
*GLOMERULOSCLEROSIS, *FOCAL segmental glomerulosclerosis, *KIDNEY failure, *NEPHROTIC syndrome, *RITUXIMAB, *DISEASE relapse
Abstract

Background Focal segmental glomerular sclerosis (FSGS) is a histologic lesion rather than a specific disease entity and represents a cluster of different conditions affecting both children and adults that includes primary, secondary and genetically mediated forms. These forms can be distinguished by electron microscopy and genetic assessment and show different responsiveness to steroids and immunosuppressants. Despite some promising effects of rituximab in nephrotic syndrome in children, the results in adults with FSGS are disappointing. Our group previously explored the effectiveness of rituximab in eight adult patients with unselected forms of FSGS and achieved a consistent reduction in proteinuria in one case. Following this experience, we developed an alternative therapeutic option intended to enhance the potential of rituximab with the support of other synergic drugs. We herein report the results of this therapeutic protocol (six administrations of rituximab plus two of intravenous cyclophosphamide plus glucocorticoids) in seven prospectively enrolled patients with extensive podocyte effacement and recurrent relapses or steroid dependence. Results Patients had a median baseline serum creatinine level of 2.2 mg/dl (range 1–4.7) that decreased to 1.1 mg/dl (range 0.9–2.2) and 1.1 mg/dl (range 0.75–2.21) after 3 and 6 months, respectively, and remained unchanged at 12 months. Three of five patients with renal failure turned to normal function while the other two patients maintained a stable impairment after 18 and 52 months. The median proteinuria decreased from 6.1 g/24 h to 3.5, 3.5 and 1.9 g/24 h at 3, 6 and 12 months, respectively. Specifically, five of seven patients had a partial response at 12 months and became non-nephrotic. One of them had a complete response at 18 months and was still in complete remission at the last follow-up visit at 36 months. Proteinuria persisted unchanged in two of seven patients with a genetic-related disease. No serious late adverse events were observed. Conclusions Our results show that intensive B-cell depletion therapy is able to reverse the nephrotic syndrome of steroid-dependent or frequently relapsing adult patients with putatively idiopathic FSGS (i.e. with extensive podocyte effacement). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

6. Additional file 1 of Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial

Author

Manzini, Paola Maria, Ciccone, Giovannino, De Rosa, Francesco Giuseppe, Cavallo, Rossana, Ghisetti, Valeria, D’Antico, Sergio, Galassi, Claudia, Saccona, Fabio, Castiglione, Anna, Birocco, Nadia, Francisci, Tiziana, Hu, Huijing, Pecoraro, Clara, Danielle, Franca, Labanca, Luciana, Bordiga, Anna Maria, Lorenzi, Marco, Camisasca, Giovanni, Giachino, Osvaldo, Pagliarino, Mauro, Ottone, Piero, Scuvera, Ilvana Tiziana Donatella, Guaschino, Roberto, Freilone, Roberto, Berti, Pierluigi, Pittaluga, Fabrizia, Avolio, Maria, Costa, Cristina, Raso, Samuele, Nucci, Aurora, Milan, Massimo, Baffa, Alessandra, Russo, Alessandra, Tornello, Antonella, Maddalena, Laura, Delios, Grazia, Marletto, Fabio Paolo, De Micheli, Anna Grazia, Mattei, Alessio, Baldassano, Stefano, Canta, Francesca, Russo, Maria Luisa, Bergamo, Daniele, Vitale, Francesco, Liccardi, Marco Maria, Chinaglia, Alessandra, Calcagno, Andrea, Converso, Marcella, Aldieri, Chiara, Libanore, Valentina, Blangetti, Ilaria, Benedetti, Valentina, Mitola, Barbara, and Scozzari, Gitana

Abstract

Additional file 1. Supplementary appendix.

Published
2022
Full Text
View/download PDF

7. L'importanza del laboratorio nella diagnosi e nella gestione della porpora trombotica trombocitopenica

Author

Valesella, Paolo, Baffa, Alessandra, Baldovino, Simone, Antonella, Vaccarino, Solfietti, Laura, Stefania, Stella, Giacomo, Quattrocchio, Roccatello, Dario, Fenoglio, Roberta, Michela, Ferro, Marchisio, Martina, Alessandra, Russo, LA GROTTA, Rita, Menegatti, Elisa, and Massimo, Milan

Subjects
porpora trombotica trombocitoprnica, medicina di laboratorio, medicina trasfusionale, malattie rare, porpora trombotica trombocitoprnica, medicina trasfusionale, malattie rare, medicina di laboratorio
Published
2021

8. Family accommodation in adult obsessive–compulsive disorder: clinical perspectives

Author

Albert,Umberto, Baffa,Alessandra, and Maina,Giuseppe

Subjects
Psychology Research and Behavior Management
Abstract

Umberto Albert,Alessandra Baffa, Giuseppe Maina Rita Levi Montalcini Department of Neuroscience, A.O.U. San Luigi Gonzaga, University of Turin, Turino, Italy Abstract: The term accommodation has been used to refer to family responses specifically related to obsessive–compulsive (OC) symptoms: it encompasses behaviors such as directly participating in compulsions, assisting a relative with obsessive–compulsive disorder (OCD) when he/she is performing a ritual, or helping him/her to avoid triggers that may precipitate obsessions and compulsions. At the opposite side, family responses to OCD may also include interfering with the rituals or actively opposing them; stopping accommodating OC symptoms or actively interfering with their performance is usually associated with greater distress and sometimes even with aggressive behaviors from the patients. This article summarizes progress of the recent research concerning family accommodation in relatives of patients with OCD. Family accommodation is a prevalent phenomenon both among parents of children/adolescents with OCD and relatives/caregivers of adult patients. It can be measured with a specific instrument, the Family Accommodation Scale, of which there are several versions available for use in clinical practice. The vast majority of both parents of children/adolescents with OCD and family members of adult patients show at least some accommodation; providing reassurances to obsessive doubts, participating in rituals and assisting the patient in avoidance are the most frequent accommodating behaviors displayed by family members. Modification of routine and modification of activities specifically due to OC symptoms have been found to be equally prevalent. Specific characteristics of patients (such as contamination/washing symptoms) and of relatives (the presence of anxiety or depressive symptoms or a family history positive for another anxiety disorder) are associated with a higher degree of family accommodation; these family members may particularly benefit from family-based cognitive–behavioral interventions. In recent years, targeting family accommodation has been suggested as a fundamental component of treatment programs and several interventions have been tested. Clinicians should be aware that family-based cognitive–behavior therapy incorporating modules to target family accommodation is more effective in reducing OC symptoms. Targeting family accommodation may be as well relevant for patients treated pharmacologically. Keywords: obsessive–compulsive disorder, family accommodation, cognitive–behavior therapy, treatment response

Published
2017

10. Family accommodation in adult obsessive-compulsive disorder: Clinical perspectives

Author

Alessandra Baffa, Umberto Albert, Giuseppe Maina, Albert, Umberto, Baffa, Alessandra, and Maina, Giuseppe

Subjects
medicine.medical_specialty, Psychology (all), Psychological intervention, Cognitive-behavior therapy, Review, family accommodation, 03 medical and health sciences, 0302 clinical medicine, obsessive–compulsive disorder, Obsessive compulsive, cognitive–behavior therapy, Family accommodation, Obsessive-compulsive disorder, Treatment response, Psychiatry and Mental Health, treatment response, Medicine, Family history positive, Psychiatry, General Psychology, Adult patients, business.industry, medicine.disease, 030227 psychiatry, Distress, Anxiety, medicine.symptom, business, Accommodation, 030217 neurology & neurosurgery, Anxiety disorder, Clinical psychology
Abstract

The term accommodation has been used to refer to family responses specifically related to obsessive-compulsive (OC) symptoms: it encompasses behaviors such as directly participating in compulsions, assisting a relative with obsessive-compulsive disorder (OCD) when he/she is performing a ritual, or helping him/her to avoid triggers that may precipitate obsessions and compulsions. At the opposite side, family responses to OCD may also include interfering with the rituals or actively opposing them; stopping accommodating OC symptoms or actively interfering with their performance is usually associated with greater distress and sometimes even with aggressive behaviors from the patients. This article summarizes progress of the recent research concerning family accommodation in relatives of patients with OCD. Family accommodation is a prevalent phenomenon both among parents of children/adolescents with OCD and relatives/caregivers of adult patients. It can be measured with a specific instrument, the Family Accommodation Scale, of which there are several versions available for use in clinical practice. The vast majority of both parents of children/adolescents with OCD and family members of adult patients show at least some accommodation; providing reassurances to obsessive doubts, participating in rituals and assisting the patient in avoidance are the most frequent accommodating behaviors displayed by family members. Modification of routine and modification of activities specifically due to OC symptoms have been found to be equally prevalent. Specific characteristics of patients (such as contamination/washing symptoms) and of relatives (the presence of anxiety or depressive symptoms or a family history positive for another anxiety disorder) are associated with a higher degree of family accommodation; these family members may particularly benefit from family-based cognitive-behavioral interventions. In recent years, targeting family accommodation has been suggested as a fundamental component of treatment programs and several interventions have been tested. Clinicians should be aware that family-based cognitive-behavior therapy incorporating modules to target family accommodation is more effective in reducing OC symptoms. Targeting family accommodation may be as well relevant for patients treated pharmacologically.

Published
2017

11. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.

Author

Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Di Perri G, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, and Rossi D

Subjects
Aged, COVID-19, Female, Humans, Male, Middle Aged, Off-Label Use, Pandemics, Pilot Projects, Prospective Studies, Receptors, Interleukin-6 antagonists & inhibitors, SARS-CoV-2, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Betacoronavirus, Coronavirus Infections therapy, Pneumonia, Viral therapy
Abstract

Objectives: No agent has yet been proven to be effective for the treatment of patients with severe COVID-19., Methods: We conducted a pilot prospective open, single-arm multicentre study on off-label use of tocilizumab (TCZ) involving 63 hospitalised adult patients (56 males, age 62.6±12.5) with severe COVID-19. Clinical and laboratory parameters were prospectively collected at baseline, day 1, 2, 7 and 14. No moderate-to-severe adverse events attributable to TCZ were recorded., Results: We observed a significant improvement in the levels of ferritin, C-reactive protein, D-dimer. The ratio of the partial pressure of oxygen (Pa02) to the fraction of inspired oxygen (Fi02) improved (mean±SD Pa02/Fi02 at admission: 152±53; at day 7: 283.73±115.9, at day 14: 302.2±126, p<0.05). The overall mortality was 11%; D-dimer level at baseline, but not IL-6 levels were predictors of mortality. TCZ administration within 6 days from admission in the hospital was associated with an increased likelihood of survival (HR 2.2 95%CI 1.3-6.7, p<0.05)., Conclusions: In hospitalised adult patients with severe COVID-19, TCZ could be a safe option. An improvement in respiratory and laboratory parameters was observed. Future controlled trials in patients with severe illness are urgently needed to confirm the definite benefit with IL-6 target therapy.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results